Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AGfiledCriticalBayer Pharma AG
Publication of AR106220A1publicationCriticalpatent/AR106220A1/en
Conjugados de ligador-fármaco homogéneo específicos de sitio de inhibidores de proteína de huso de quinesina, a metabolitos activos de estos conjugados, a procesos para preparar estos conjugados, al uso de estos conjugados para el tratamiento y/o la prevención de enfermedades y al uso de estos conjugados para preparar medicamentos para el tratamiento y/o la prevención de enfermedades, en particular trastornos hiperproliferativos y/o trastornos angiogénicos tales como, por ejemplo, enfermedades cancerosas. Estos tratamientos se pueden realizar como monoterapia o incluso en combinación con otros medicamentos u otras medidas terapéuticas.Site-specific homogeneous linker-drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes to prepare these conjugates, to the use of these conjugates for the treatment and / or prevention of diseases and to the use of these conjugates to prepare medicaments for the treatment and / or prevention of diseases, in particular hyperproliferative disorders and / or angiogenic disorders such as, for example, cancerous diseases. These treatments can be performed as monotherapy or even in combination with other medications or other therapeutic measures.
ARP160101869A2015-06-232016-06-22
SPECIFIC HOMOGENIC SITE CONNECTORS WITH KSP INHIBITORS
AR106220A1
(en)
Treatment of breast cancer using a combination of a cationic liposomal formulation of taxane, a non-liposomal formulation of taxane and a further active agent.